---
title: "Promising Clinical Data and Strategic Uncertainties: Analyst Recommends ‘Buy’ for I-MAB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262870165.md"
description: "Analyst Andres Y. Maldonado has issued a 'Buy' rating for I-MAB, driven by promising clinical data for its lead asset, givastomig, which showed an 18% objective response rate in metastatic gastric cancer patients. Despite strategic uncertainties from the company's transformation and planned IPO in Hong Kong, the analyst remains optimistic about the drug's potential. BTIG also reiterated a 'Buy' rating with a $9.00 price target. Maldonado has a 23.5% average return and 53.59% success rate on recommended stocks."
datetime: "2025-10-27T10:26:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262870165.md)
  - [en](https://longbridge.com/en/news/262870165.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262870165.md)
---

# Promising Clinical Data and Strategic Uncertainties: Analyst Recommends ‘Buy’ for I-MAB

Andres Y. Maldonado has given his Buy rating due to a combination of factors, primarily centered around the promising clinical data for I-MAB’s lead asset, givastomig. The recent Phase 1 monotherapy results presented at a major conference highlighted an 18% objective response rate in heavily pre-treated metastatic gastric cancer patients, showcasing the drug’s potential as a best-in-class treatment. The durability of responses, with some lasting up to 33 months, and a favorable safety profile further bolster confidence in its clinical prospects.  
Despite the positive clinical outlook, Maldonado acknowledges the strategic uncertainties introduced by I-MAB’s ongoing corporate transformation. The company’s shift towards a new brand and business model, along with a planned IPO in Hong Kong, could impact capital allocation and focus. However, the analyst remains optimistic about givastomig’s role as a primary value driver, while also noting the need for careful management of resources to ensure the company’s oncology focus remains intact.

Y. Maldonado covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, Protara Therapeutics, and Corbus Pharmaceuticals. According to TipRanks, Y. Maldonado has an average return of 23.5% and a 53.59% success rate on recommended stocks.

In another report released on October 24, BTIG also reiterated a Buy rating on the stock with a $9.00 price target.

### Related Stocks

- [IMAB.US](https://longbridge.com/en/quote/IMAB.US.md)
- [NBP.US](https://longbridge.com/en/quote/NBP.US.md)

## Related News & Research

- [FBT and IBB are not the same biotech bet, and 5 years of returns prove it](https://longbridge.com/en/news/293926015.md)
- [Rhythm Pharmaceuticals (RYTM) Faces A Big Undervaluation Call, Is The Upside Already Priced In?](https://longbridge.com/en/news/293893019.md)
- [Gossamer Bio shareholders approved convertible note exchange proposals at special meeting](https://longbridge.com/en/news/293920719.md)
- [Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition](https://longbridge.com/en/news/293936488.md)
- [Q32 Bio Inc. (NASDAQ:QTTB) Sees Large Increase in Short Interest](https://longbridge.com/en/news/293861610.md)